CVM News and Press, Cel-Sci Corporation

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...

2024-05-16 09:27:11 ET More on Cel-Sci CEL-SCI gains as FDA greenlights confirmatory study for Multikine Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci Read the full article on S...

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and D...

2024-05-08 09:33:30 ET More on Cel-Sci Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci Read the full article on Seeking...

Critical milestone achieved—the FDA accepted CEL-SCI’s selection criteria defining the Multikine target population before surgery Selected patient population had 73% survival with Multikine vs. 45% without Multikine based on analysis of completed 928-patient Phase 3 rand...

CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as in...

CEL-4000 may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weakening important immune defense mechanisms, risking infections or cancer, as current treatments may CEL-SCI Corporation (NYSE American: CVM) today announced the peer rev...

2024-02-15 08:10:32 ET More on Cel-Sci Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA CEL-SCI spikes as U.K. picks cancer drug, Multikine for review Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Finan...

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: CEL-SCI identified the target head and neck cancer patient popul...